Usefulness and Limitations of Rituximab in Managing Patients With Lymphoproliferative Disorder After Heart Transplantation
| Autor: | Marie-Hélène Leblanc, Sabrina Demers, Christine Bourgault, Bernard Cantin, Mario Sénéchal, Joëlle Morin, Christian Couture |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Lymphoproliferative disorders Gastroenterology Antibodies Monoclonal Murine-Derived Young Adult Postoperative Complications immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans Immunologic Factors Young adult Heart transplantation CD20 Transplantation biology business.industry Mortality rate Remission Induction Middle Aged medicine.disease Lymphoproliferative Disorders Treatment Outcome Immunology biology.protein Heart Transplantation Female Rituximab Complication business Progressive disease medicine.drug |
| Zdroj: | Experimental and Clinical Transplantation. 10:513-518 |
| ISSN: | 2146-8427 1304-0855 |
| DOI: | 10.6002/ect.2012.0012 |
| Popis: | Posttransplant lymphoproliferative disorders remain an uncommon complication of heart transplant with a high mortality rate reported after conventional therapies. Four patients with posttransplant lymphoproliferative disorders, of whom 3 were CD20 positive, received intravenous dosages of rituximab, 375 mg/m(2), weekly, for 6 ± 2 weeks. The overall response rate was 75% with 3 complete responses (CD20 positive) and 1 case of progressive disease (CD20 negative). Rituximab should be considered as a first-line therapy for patients with CD20 positive posttransplant lymphoproliferative disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|